share_log

Oppenheimer Initiates Coverage On Entrada Therapeutics With Outperform Rating, Announces Price Target of $22

Oppenheimer Initiates Coverage On Entrada Therapeutics With Outperform Rating, Announces Price Target of $22

奥本海默以跑赢大盘的评级开始对Entrada Therapeutics进行报道,宣布目标股价为22美元
Benzinga ·  01/05 07:23

Oppenheimer analyst Hartaj Singh initiates coverage on Entrada Therapeutics (NASDAQ:TRDA) with a Outperform rating and announces Price Target of $22.

奥本海默分析师哈塔杰·辛格以跑赢大盘的评级开始对Entrada Therapeutics(纳斯达克股票代码:TRDA)进行报道,并宣布目标股价为22美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发